

EUFEPS Virtual Annual meeting 2021 – Bridging the gap between the patient and product design

Preliminary Program June 9 - all sessions live

(All plenary lectures and the parallel session to the left in **Room A** on platform, parallel session to the right in **Room B**)

09:00	Award Ceremony Prof. Dr. Dieter Steinhilber, Goethe University, Germany/ President EUFEPS	
	Model-based drug development and treatment optimization for tuberculosis	Big pharmacogenomics data- from bench to bedside and back again
	Chairs: Coen van Hasselt, Leiden University, NL and Rob van Wijk, Leiden University, NL	Chair: Ana Alfirevic, University of Liverpool, UK
09:15	Mechanistic translational PKPD modelling to support tuberculosis drug development <i>Ulrika Simonsson</i> , Uppsala University, Sweden	Pharmacoeconomic considerations for pharmacogenetic testing <i>Dyfrig Hughes</i> , Bangor University, School of Health Sciences, UK
09:40	Zebrafish as a translational model for PK/PD of anti-TB drugs <i>Rob van Wijk</i> , Leiden University, NL	Strategy to boost the brain delivery of a NMDAR antagonist by targeting drug transporters at the blood-brain barrier <i>David Dickens</i> , University of Liverpool, UK
09:55	Coffee Break	
	Frontiers in Drug Discovery	Regulatory science 2025: from Science to Regulators
	Chairs: Dieter Steinhilber, Goethe University, Germany and Michael Sundström, Karolinska Institutet, Sweden	Chair: <i>Hubert Leufkens</i> , UIPS, Netherlands
10:10	The SGC Target Discovery Public-Private Partnership: Status and Plans for 2020-25 <i>Michael Sundström</i> , CMM, Karolinska Institutet, SGC	Innovation and regulation in Advanced Therapeutic Medicinal Products (ATMPs) <i>Miguel Forte</i> , Bone Therapeutics, Belgium
10:35	Platformization – A High Throughput Protein Engineering Platform for the Development of Multispecific Protein Therapeutics <i>Thorsten Schmidt</i> , Sanofi, Germany	International challenges and opportunities for regulatory sciences <i>Rogério Gaspar</i> , University of Lisbon, Portugal

11:05	Glutathione peroxidases 1 and 2 as promising targets in anti-inflammatory therapy <i>Solveigh Koeberle, University of Innsbruck, Austria</i>	Where is regulatory science moving in the next decade? <i>Hubert Leufkens, UIPS, Netherlands</i>
11:20	Lunch	
	Selecting the right animal model in medicines development	Challenges in biosimilarity assessment
	Chair: Ivo Schmerold, University of Veterinary Medicine, Austria	Chairs: Henning Blume, SocraTec C&S, Germany and Jan Welink, Medicines Evaluation Board, Netherlands
1230	Large animal infra center – collaboration between veterinary and human medicine <i>Henrik Rönnberg, Swedish University of Agricultural Sciences, Sweden</i>	Biosimilars: the European concept of comparability exercise <i>Martina Weise, BfArM, Germany</i>
1255-13:20	Reverse Translational Pharmacology: Paradigm Shift or Flash in the Pan? <i>Jonathan Mochel, Iowa State University College of Veterinary Medicine, USA</i>	PK characteristics for biosimilarity assessment and impact of ADA formation <i>Henning Blume, SocraTec C&S, Germany</i>
13:25-13:40	EUFEPS Annual Meeting Leiden 2022 and Closing remarks Prof. Dr. Anke-Hilse Maitland-van der Zee and Prof. Dr. Dieter Steinhilber, President EUFEPS	

Each lecture will include 5 min (short lecture 2 min) Q&A where questions are posted by chat and questions raised verbally by chair.